PMID: 11921320Mar 29, 2002Paper

Estimating survival gain for economic evaluations with survival time as principal endpoint: a cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer

Health Economics
N NeymarkM Bolla

Abstract

The problem of estimating expected outcomes for the economic evaluation of treatments for which the outcome of principal interest is (quality adjusted) survival time has so far not received sufficient attention in the literature. The best estimate of expected survival is mean survival time, but with censored survival data, the true survival time for all the subjects is not known, so the mean is not defined.A possible solution to this estimation problem is illustrated by a retrospective cost-effectiveness analysis of the addition of hormonal therapy to standard radiotherapy for patients with locally advanced prostate cancer. A recently proposed method is used to approach the problem caused by censored cost data, and the impact of uncertainty is assessed by bootstrap resampling techniques. Mean survival time is estimated by a restricted means analysis with the time point of restriction determined by statistical criteria. When average total costs and mean survival time is evaluated at this time point of restriction, the result is that the combined therapy (radiotherapy plus hormonal therapy) increases mean survival time by about 1 year, while reducing the costs per patient for the French health insurance system by 12 700 FF. The t...Continue Reading

References

Jan 1, 1977·British Journal of Haematology·J Palek
Jul 1, 1996·Medical Decision Making : an International Journal of the Society for Medical Decision Making·B O'Brien, A Gafni
Feb 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W McGuireC M Dezii
Aug 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A MessoriE Tendi
Jul 22, 1998·Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer·N Neymark
Jul 22, 1998·Statistics in Medicine·P P GlasziouR J Simes
Aug 6, 1998·The New England Journal of Medicine·J C Wright, M C Weinstein
Nov 3, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·N Neymark
Sep 4, 1998·Journal of Health Services Research & Policy·A Briggs, A Gray
May 29, 1999·Health Economics·D F HeitjanW Whang
May 29, 1999·Health Economics·A H Briggs
Jul 29, 1999·Medical Decision Making : an International Journal of the Society for Medical Decision Making·H A GlickK A Schulman
Feb 16, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·T J IvesonE Van Cutsem
Apr 28, 2000·BMJ : British Medical Journal·S G Thompson, J A Barber

❮ Previous
Next ❯

Citations

Jan 12, 2007·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Mathias LidgrenBengt Jönsson
Feb 23, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R Crott, N Neymark
Sep 5, 2003·Urologic Oncology·Beth A Hellerstedt, Kenneth J Pienta
Apr 4, 2007·PharmacoEconomics·Steven B Zeliadt, David F Penson
Feb 7, 2014·International Journal of Technology Assessment in Health Care·Michael BäumlerDaniel Böhringer
Aug 6, 2013·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Luis MendonçaJosé Fragata
Mar 12, 2004·Expert Opinion on Pharmacotherapy·Andre KonskiUNKNOWN RTOG (Radiation Therapy Oncology Group) Outcomes Model
Jun 3, 2008·Seminars in Radiation Oncology·Andre Konski
Jul 15, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Fatma AtamanMichel Bolla
Jul 29, 2015·Pharmaceutical Statistics·Karen E LambJohn B Carlin
Jan 16, 2008·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Ben BrownPaul Robinson
Jun 19, 2009·Medical Care·Joseph LipscombK Robin Yabroff
Apr 11, 2013·Expert Review of Pharmacoeconomics & Outcomes Research·Hind T HatoumDennis C Marshall
Sep 8, 2006·Australian and New Zealand Journal of Public Health·Marian ShanahanJoanne Ross

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Expert Review of Pharmacoeconomics & Outcomes Research
Timo T Purmonen
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
S IannazzoM Perachino
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
John B Watkins
© 2022 Meta ULC. All rights reserved